AllPennyStocks.com Why Is EVMN Stock Down 13% After-Hours?
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Why Is EVMN Stock Down 13% After-Hours?

Evommune said on Tuesday that its mid-stage trial involving its experimental eczema pill EVO756 failed a mid-stage study.

Other Penny Stock Movers

Digestive Health Expansion Sends This Microcap Soaring
Utah Copper Explorer Jumps 19% on Surface Assays
Indonesian Gold Developer Jumps 27% as Ministry Moves File to Final Approval
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top